

To
The Manager (Listing)
BSE Limited
Phiroz Jeejeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Date: 14.11.2025

Scrip Code: 530313 [KIMIABL]

Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Respected Sir/Madam,

In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held today i.e. 14th November, 2025 at 7:00 P.M(IST) at the corporate office of the company ,situated at 974, 9th floor, Aggarwal Millenium Tower-II ,Netaji Subhash Place, New Delhi-110034 and the following buisnesses, amongst others, were transacted at the meeting of Board of Directors.

- 1) Approval of Unaudited financial results of the Company, on standalone basis, for the quarter and half year ended September 30th ,2025 in accordance with the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taking on record the limited Review Report issued by the Statutory Auditors of the Company.(copy attached as **Annexure A**).

The Board Meeting commenced at 07:00 PM and concluded at 08.00 PM.

This is for your kind information and record.

Thanking You

For **KIMIA BIOSCIENCES LIMITED**

Pallavi
Garg

Digitally signed
by Pallavi Garg
Date: 2025.11.14
19:52:30 +05'30'

Pallavi Garg
Company Secretary & Compliance officer
Place: New Delhi

KIMIA BIOSCIENCES LIMITED

Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana-122102
Tel.: +91 9654746544, 9654206544

Corporate Office
974, 9th Floor, Aggarwal Millennium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel.: +91 11 47063600, 470630601



Review Report

To
The Board of Directors
Kimia Biosciences Limited
Village Bhondsi, Tehsil Sohna
Gurgaon Haryana-122102

1. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the quarter ended September 30, 2025 (the "Statement") and year to date results for the period from April 01, 2025 to September 30, 2025, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. Review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Neeraj Arora & Associates
FRN: 021309N

Neeraj Kumar Arora
M. No. 510750
UDIN:- 25510750BMIEJG6625
Place:- Gurugram
Dated:- November 14, 2025



KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025****STATEMENT OF ASSETS, EQUITY and LIABILITIES**


S. No.	Particulars	As at 30-09-2025 (Unaudited)	As at 31-03-2025 (Audited)
A	ASSETS		
1	Non-Current Assets		
	Property, Plant & Equipment	2,954.75	3,046.06
	Capital Work-in-Progress	-	0.32
	Right of Use Assets	34.08	43.82
	Intangible Assets	394.64	237.82
	Financial Assets		
	(i) Other Non Current Financial Assets	41.63	40.88
	Deferred Tax Assets (Net)	174.02	176.25
	Other Non-current Assets	-	46.85
2	Current Assets		
	Inventories	3,465.22	3,458.31
	Financial Assets		
	(i) Investment	-	-
	(ii) Trade Receivables	2,818.30	3,675.09
	(iii) Cash and Cash Equivalents	20.97	20.61
	(iv) Bank balances other than (iii) above	50.09	47.49
	(v) Other Current Financial Assets	112.31	105.54
	Current Tax Assets (Net)	69.77	67.94
	Other Current Assets	13.40	154.18
	Total Assets	10,149.18	11,121.16

S. No.	Particulars	As at 30-09-2025 (Unaudited)	As at 31-03-2025 (Audited)
B	EQUITY & LIABILITIES		
1	EQUITY		
	(a) Share Capital	473.13	473.13
	(b) Other Equity	685.39	523.48
2	NON CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	1,630.00	1,037.01
	(ii) Lease Liabilities	17.14	27.59
	(iii) Other financial liabilities	-	632.97
	Provisions	173.52	159.67
	Other Non-Current Liabilities	-	84.81
3	CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	1,940.96	2,219.62
	(ii) Lease Liabilities	20.13	18.62
	(iii) Trade Payables		
	a. Total Outstanding due to Micro and Small Enterprises	4.73	4.73
	b. Total Outstanding due to other than Micro and Small Enterprises	4,782.13	5,044.16
	(iii) Other Financial Liabilities	434.36	490.56
	Other Current Liabilities	(12.31)	395.08
	Provisions	-	9.73
	Total Equity and Liabilities	10,149.18	11,121.16

Other Notes

1 The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS

FOR KIMIA BIOSCIENCES LIMITED


 Sameer Goel
 (Managing Director & CEO)

DIN - 00161786

Date: November 14, 2025

Place: New Delhi




KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			Half Year Ended		Year Ended
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	3,399.93	2,358.41	2,817.86	5,758.34	5,057.79	11,892.08
II	Other Income	(33.17)	84.69	37.09	51.52	45.42	132.03
III	Total Income (I+II)	3,366.76	2,443.10	2,854.95	5,809.86	5,103.21	12,024.11
IV	Expenses:						
	a) Cost of materials consumed	1,771.04	1,706.19	1,746.35	3,477.23	3,243.57	7,455.02
	b) Change in inventories of finished goods and work-in-progress	474.77	(290.32)	(20.95)	184.45	(295.52)	(368.23)
	c) Employee benefits expenses	330.83	327.67	352.45	658.50	695.28	1,367.89
	d) Finance costs	26.70	174.71	103.93	201.41	214.77	455.70
	e) Depreciation and amortisation expense	97.13	93.53	78.64	190.66	168.42	337.89
	f) Other expenses	571.29	362.18	403.10	933.47	707.06	1,412.42
V	Total Expenses (IV)	3,271.76	2,373.96	2,663.52	5,645.72	4,733.58	10,660.69
VI	Profit/(loss) before exceptional items and Tax (III-V)	95.00	69.14	191.43	164.14	369.63	1,363.42
VII	Exceptional Items	-	-	-	-	-	-
VI	Profit/(loss) before tax (IV-V)	95.00	69.14	191.43	164.14	369.63	1,363.42
VII	Tax expenses:						
	a) Current Tax	-	-	31.95	-	61.69	-
	b) Deferred Tax charge / (credit)	(6.51)	8.74	(1.86)	2.23	2.90	402.18
VIII	Profit/(loss) for the period (VI-VII)	101.51	60.40	161.34	161.91	305.04	961.24
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
	- Remeasurement of defined benefit plans	-	-	-	-	-	3.04
B.	Items that will be reclassified to Profit or Loss (Net of Tax)						(0.77)
X	Total Comprehensive Income for the period (VIII+IX)	101.51	60.40	161.34	161.91	305.04	963.51
XI	Paid up equity share capital (Face value of Rs. 1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	Other Equity						
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	0.21	0.13	0.34	0.34	0.64	2.03
	Diluted in Rs.	0.21	0.13	0.34	0.34	0.64	2.03

Other Notes


- 1 The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.

FOR KIMIA BIOSCIENCES LIMITED

Sameer Goel
(Managing Director & CEO)
DIN - 00161786

Date: November 14, 2025

Place: New Delhi



KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**STATEMENT OF CASH FLOWS**

Particulars	For the half year ended 30-09-2025 (Unaudited)	For the half year ended 30-09-2024 (Unaudited)
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before tax	164.14	369.63
Adjustment for:		
Depreciation and amortization expense	190.66	168.42
Finance costs	201.41	214.77
Gain on fair value of investment in mutual funds	-	-
Interest income	(2.61)	-
Deferred revenue income	-	(0.68)
Unrealised (gain)/loss on foreign currency transactions and translations	-	-
Operating Profit Before Working Capital Changes	553.60	752.14
Adjustments for:		
(Increase) / Decrease in inventories	(6.91)	(287.57)
(Increase)/ Decrease in trade and other receivables	993.49	275.05
Increase/ (Decrease) in trade and other payables	(1,405.30)	139.56
Increase/ (Decrease) in Lease Liabilities	(8.94)	-
Cash Generated From Operations	125.94	879.18
Less : Income tax paid/ (refunds)	(1.83)	2.71
Net Cash From Operating Activities	124.11	881.89
B. Cash Flow from Investment Activities		
Purchases of property, plant and equipments including intangible assets & capital advances	(202.70)	(95.03)
Net inflow / (outflow) in fixed deposits	(2.60)	(5.69)
Purchase of current investments	-	-
Interest received	2.61	0.68
Net Cash Used In Investing Activities	(202.69)	(100.04)
C. Cash Flow from Financing Activities		
Receipts from non current borrowings	547.15	-
Repayment of non current borrowings	45.84	(333.55)
Net proceeds of current borrowings	(278.66)	(192.78)
Finance costs paid	(235.39)	(237.72)
Net Cash Used in Financing Activities	78.94	(764.05)
Net Increase/(Decrease) in Cash and Cash Equivalents	0.36	17.81
Cash and Cash Equivalents at the beginning of the period	20.61	18.46
Cash and Cash Equivalents at the end of the period	20.97	33.22


Other Notes

1 The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'

FOR KIMIA BIOSCIENCES LIMITED

Date: November 14, 2025

Place: New Delhi


Sameer Goel
(Managing Director & CEO)
DIN - 00161786

